Biogen's (BIIB) "P&L Remains Challenged", Focus on CLARITY-AD - BMO Maintains Stock at Market Perform
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $217.00 price target on Biogen (NASDAQ: BIIB), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
